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Abstract
Background: Left atrial appendage (LAA) closure (LAAC) is a viable alternative to anticoagula-
tion for stroke prevention in non-valvular atrial fibrillation. However, device-associated thrombosis 
(DAT) is known as a complication of LAAC as observed within the first few weeks after implantation. 
A noninvasive method is needed to predict the progress for endothelialization surveillance. The aim of 
the study was to develop a noninvasive visual contrast-enhanced transesophageal echocardiography 
(cTEE) method for monitoring the communication between left atrium (LA) and LAA post-LAAC by 
cTEE-score evaluating the contrast enhancement in LAA.
Methods: A total of 29 healthy dogs were studied by LAAC at < 24 h and 1, 2, 3 and 6-months. The 
LAAC procedure was assessed by TEE with color Doppler flow imaging (CDFI) and contrast imaging. 
The cTEE score was calculated based on the differential contrast opacification of LA and LAA cavities, 
the CDFI on the width of peri-device color flow, and that of histology on the level of occluder surface 
endothelialization in postmortem histological examination. Spearman’s correlation analysis was used 
to correlate these scores. 
Results: The correlation between cTEE and histology scores was superior to that between CDFI and 
histology scores. The trend of average cTEE score was tracked with that of histology, while that of CDFI 
was far from that of histology. The correlation coefficient of CDFI and histology scores was not signifi-
cant (p > 0.05). 
Conclusions: The noninvasive visual cTEE is feasible and reliable to monitor communication be-
tween the LA and LAA post-LAAC. cTEE is superior to CDFI as a tool in predicting the progress for 
endothelialization surveillance. (Cardiol J)
Key words: left atrial appendage closure, endothelialization, contrast echocardiography, 
histology, noninvasive surveillance
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Introduction
Left atrial appendage closure (LAAC) is an 
important alternative to life-long oral anticoagula-
tion (OAC) in patients with high stroke risk and 
contraindication for OAC [1]. The Watchman de-
vice (Boston Scientific Inc., USA) and Amplatzer 
Cardiac Plug (ACP) device (St. Jude Medical Inc., 
USA) are the most commonly used devices [1–3]. 
Clinical trials with the Watchman device suggested 
that LAAC was similar to warfarin therapy for 
stroke prevention in non-valvular atrial fibrilla-
tion patients [4, 5]. The 5-year outcomes of the 
PREVAIL and the PROTECTAF trials demonstrat-
ed that LAAC by the Watchman device prevented 
stroke in non-valvular atrial fibrillation as compared 
to warfarin with fewer hemorrhagic strokes and 
mortalities [6, 7].
Interestingly, if the foreign material of LAAC 
devices is not fully covered by endothelial cells, 
thrombus develops on the left atrial surface of 
the device, followed by thromboembolization [8]. 
Reportedly, device-associated thrombosis (DAT) 
is a complication that occurs after LAAC with an 
incidence of 0–17.6% [1, 8–13]. Typically, the in-
cidence of thrombus formation is frequent in the 
first few weeks after LAAC, followed by a decline 
with complete endothelialization of the device 
surface [10]. DAT and the peri-device leak showed 
a correlation with late thromboembolic events after 
technically successful LAAC [12]. Therefore, the 
optimal regimen of post-procedural anticoagulation 
or platelet inhibition after LAAC is recommended 
for both the Watchman and ACP devices [11]. 
However, the correlation between endotheli-
alization of the left atrial appendage (LAA) occluder 
surface during healing and the blood flow between 
the left atrium (LA) and LAA is yet to be elucidated. 
The communication flow between LA and LAA, 
including central-device flow and peri-device flow 
(residual flow), may be associated with incomplete 
endothelialization of occluder surface and the risk 
of DAT formation. Both color Doppler flow imag-
ing (CDFI) and contrast-enhanced transesophageal 
echocardiography (cTEE) is used to monitor the 
blood flow [14]. CDFI has been used to identify 
the residue flow by measuring the width of peri-
device flow in PROTECTAF, PREVAIL, and EVO-
LUTION trials [4, 5]. However, the use of cTEE 
for post-LAAC follow-up examination has not yet 
been explored despite it being a valuable tool for 
differentiating between spontaneous contrast and 
thrombus in LAA [14]. 
Herein, we sought to monitor the commu-
nication between LA and LAA by applying cTEE 
after LAAC and found complete closure of LAA 
and endothelialization of the surface of the device 
in the absence of contrast agent within the LAA. 
However, the LAA opacification indicated the 
presence of communication between LA and LAA, 
although it could not be quantified. Furthermore, 
the correlation between CDFI, cTEE, and endothe-
lialization is unclear.
Because complete cessation of flow by CDFI 
is the current “gold standard” for discontinua-
tion of anticoagulation post-LAAC clinically, we 
focused on the correlation between cTEE, CDFI, 
and the histological evidence of complete endothe-
lialization. In this study, we proposed that cTEE is 
a noninvasive method to evaluate not only the 
LAAC effectiveness  but also the degree of en-
dothelialization (related to histological analysis) 
and that it is a superior tool to CDFI for endothe-
lialization surveillance.  
Methods
Animal preparation
A total of 29 healthy dogs (7 females, 28.0 ± 
± 3.7 kg) were divided into five groups randomly 
and euthanized at < 24 h, 1-, 2-, 3-, and 6-months 
after LAA device implantation. The study proto-
col was approved by the Committee on Animal 
Research of Beijing Pinggu District Hospital’s 
Animal Experimental Center (Beijing, China). For 
the LAAC procedure and follow-up transesophageal 
echocardiography (TEE) examinations, the animals 
were under general anesthesia with xylazine hydro-
chloride (0.1 mg/kg) and propofol intramuscularly 
after 12 h of fasting.
TEE and cTEE examinations
A GE Vivid E9 with XD clear ultrasound 
system (GE Vingmed Ultrasound AS, Norway) 
containing a 6VT-D TEE transducer (3–8 MHz) 
was used. The TEE probe was inserted at a depth 
of 50–60 cm from the incisors. At 0, 45–60, 80–90, 
and 120–135°, the following were recorded: the 
LAA lobes, orifice diameter and depth, and the 
distance between left superior pulmonary vein and 
mitral annulus. The peri-device flow post-LAAC 
was assessed by CDFI with > 10 frames/s. 
By adjusting in the left ventricular contrast 
mode, the mechanical index was set between 
0.3 and 0.4, while the soft tissue thermal index 
was 0.2. After focusing the LAA and placing the 
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sample volume on the LAA orifice, 1.0–1.5 mL 
contrast agent (SonoVueTM, Bracco Diagnostics, 
Princeton, NJ, USA) was injected intravenously in 
the femoral vein by bolus application, followed by 
a flush of saline. The images were acquired in 3–5 
cardiac cycles after microbubbles was gradually 
flushed into the LAA. The time intensity curves 
of micobubble concentrations were acquired from 
the sample points (2.0-mm high and 2.0-mm wide). 
The curves were fitted using Time Intensity Curve 
Manual (Ultrasound Lab, 2005) and: Fitting Curve 
= A [1 – exp(–kt)] + B, where A is the difference 
between B and the maximum intensity at t is infinity, 
B is the intercept intensity at t = 0, k is a constant, 
1 – exp(–kt) is the increasing function for wash-in.
The definition of cTEE score is three scores: 
2, 1, and 0. The cTEE score of 2 is defined as 
microbubbles in both LA and LAA simultaneously 
with in 3 heart beats that fully fill the LAA, and 
1 as microbubbles that slowly appear in LAA, fol-
lowing 3–5 heartbeats after LA is fully or partially 
filled. The final filling of LAA may be partial or 
complete. The cTEE score of 0 is defined as non-
visible microbubbles in LAA, in which, there is no 
communication between LA and LAA. The cTEE 
scores 2 and 1 represent at least partial blood flow 
between LA and LAA. 
The CDFI scores are based on the width of 
the residual flow into LAA. The CDFI score of 2 is 
defined as the width of peri-device flow > 5 mm, 
1 as the width of peri-device flow ≤ 5 mm, and 0 as 
non-detectable peri-device flow.
LAA occlusion
The procedure was performed through a femo-
ral vein under fluoroscopic and angiographic guid-
ance. Based on the measurements by angiography 
and TEE, a self-expanding device (LAMaxTM LAAC 
occluder, ShenZhen KYD Biomedical Technology 
Co., Ltd, China) was chosen, which comprises 
a proximal cover-disc to seal the ostium of the LAA 
and a distal embedded-hook anchor to be positioned 
within the LAA; a short central waist was connected 
with the two parts. Both the disc and the anchor 
were constructed from nitinol mesh and incorporate 
with fabric. Prior to the device release, five signs 
(acronym COVER) should be observed: 1) Conca-
vity of the cover-disc to ensure adequate sealing; 
2) Oversizing, i.e., the diameter of the anchor is 
20–50% larger than the measured zone; 3) Verifying 
the position and impingement on the surrounding 
structures; 4) Ensuring stability for tug test; and 
5) Residual flow assessed to be < 5 mm.
Follow-up gross and microscopic  
examinations
After postoperative TEEs, the dogs were 
euthanized with an overdose of intravenous injec-
tion of pentobarbital (86 mg/kg). The chest and 
pericardial cavities were inspected. The heart was 
opened from the right atrial. The device migra-
tion, DAT, the surface of the cover-disc, and the 
correlation with left superior pulmonary vein and 
mitral annulus were analyzed. The anchor of the 
device was inspected by cutting through the LAA. 
A histology score of 2 is defined as no neo-intimal 
coverage on the atrial surface of the cover-disc, 1 
as partial neo-intimal coverage on the atrial surface 
or full neo-intimal coverage but gaps are present 
between the periphery of the cover-disc and the LA 
tissue, indicating incomplete LAAC, and 0 as full 
neo-intimal coverage on the surface of the cover-
disc without any gap between the periphery of the 
cover-disc and the LA tissue, indicating complete 
LAA occlusion.
Subsequently, the device and the surrounding 
tissue underwent dehydration, followed by infiltra-
tion and were embedded in methyl methacrylate. 
The device was cut along the long axis of the ap-
pendage with an EXAKT 300CP diamond band saw, 
polished with an EXAKT 400CS grinding system 
(EXAKT, Norderstedt, Germany), stained with 
toluidine blue, and analyzed under light microscopy.
Statistical methods
Data were analyzed using SPSS version 21.0 
(SPSS Inc., Chicago, IL, USA). Values were dis-
played as mean ± standard deviation (SD). Spear-
man’s correlation coefficients were computed 
among the cTEE, CDFI, and histology scores. 
P < 0.05 was considered statistically significant. 
The total scores were computed as the sum of the 
scores of all accountable dogs at that time point. 
The average score was computed by using total 
score divided by the animal count in a group. Plots 
were created with Microsoft Excel.
Results
Transesophageal echocardiography was per-
formed in 29 dogs before LAAC. At 3–5 s after the 
intravenous injection of contrast agent, microbub-
bles could be seen filling the LAA (Fig. 1). No con-
trast filling defect was detected in any of them. The 
success of device implantation was 100%. There 
was no evidence of infarction in the major organs, 
as assessed by gross examinations.
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At the follow-up visit, all animals had TEEs. 
The post-mortem pathology showed the LAA 
orifices were occluded by the cover-disc, and no 
thrombi were detected at any of these stages. 
Beginning from 1-month post LAAC, the atrial 
surface of the cover-discs started to be covered by 
a glistening white neo-endocardial layer. Bytheen-
dof 6-month, the neo-endocardialization was 100% 
(Table 1). The neo-intima covered the device-left 
atrial interfaces, thereby sealing the LAA orifices 
completely. The claws of the anchor were well 
opposed to the LAA walls, without any evidence 
of tissue necrosis. 
Figures 2 and 3 present examples of cTEE 
scores 0, and 2, respectively. As shown in Figure 4, 
the local atrial tissue tolerated the device well, as 
shown histologically.
Table 1 summarizes the results of cTEE-score, 
peri-device flow detected by CDFI, and histology 
score. In Table 2, at the < 24 h time point, only 17 
dogs exhibited cTEE scores; the average cTEE 
score was 1.41. The average CDFI-score of 29 dogs 
Figure 1. Representative contrast-enhanced transesophageal echocardiography (cTEE) graphs of different score 
gradings; A. cTEE-score 2: Microbubbles appeared in both left atrium (LA) and left atrial appendage (LAA) simultane-
ously within 3 heart beats, and fully filled in LAA; both time intensity curves (TIC) for the concentrations in LA (yellow 
TIC) and LAA (green TIC) were mingled and reached their plateaus at the same time; B. cTEE-score 1: Microbubbles 
appear slowly in LAA by 3 heart beats after the LA was fully filled with microbubbles; the rising speed of TIC in LAA 
(green) was slower than the one in LA (yellow), and finally both TICs mixed together although the yellow TIC reached 
its plateau earlier; C. cTEE-score 0: None visible microbubble in LAA, both TICs were separated with the TIC in LAA 
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was 0.17. Six dogs were sacrificed for autopsy. The 
average cTEE, CDFI and histology scores of these 
6 dogs were 1.5, 0, and 2, respectively. 
At the 1-month time point, the 6 dogs were 
sacrificed. The average cTEE, CDFI and histology 
scores of these dogs were 0.5, 0 and 0.5, respec-
tively. One device malposition was found with 
a histology score of 1 (Case No. 11, Table 3). At the 
2-month time point, no device migration was found. 
At the 3-month time point, 7 dogs were sac-
rificed. Their average cTEE, CDFI and histology 
scores were 0.71, 0.29 and 0.57, respectively. 
There was peri-device flow in 2 cases (Case No. 21 
and 24) with a width of 2-mm detected by a CDFI 
and cTEE score of 2 or 1 at post-LAAC. CDFI dem-
onstrated that 3/7 animals had peri-device flow at 
both < 24 h and 1-month post-LAAC time points. 
Among these 3 animals, a peri-device flow was no 
longer apparent at 2 months, as assessed by CDFI 
but was detected by cTEE (Table 1). At the 6-month 
time point, the cTEE, CDFI, and histology scores of 
the remaining dogs were 0. The LSPV was partially 
obstructed and the MA was compressed by the 
cover-disc of the same device.
Table 1. Results of contrast-enhanced transesophageal echocardiography (cTEE)-score, peri-device 
flow detected by color Doppler flow imaging (CDFI)-score, and histology score.
Group Case  
No.




< 24 h 1 m 2 m 3 m 6 m < 24 h 1 m 2 m 3 m 6 m
< 24 h 1 2 – – – – 0 – – – – 2
2 1 – – – – 0 – – – – 2
3 1 – – – – 0 – – – – 2
4 1 – – – – 0 – – – – 2
5 2 – – – – 0 – – – – 2
6 2 – – – – 0 – – – – 2
1–month 7 0 – – – 0 0 – – – 0
8 1 – – – 0 0 – – – 1
9 1 – – – 0 0 – – – 1
10 0 – – – 0 0 – – – 0
11 1 – – – 2 0 – – – 1
12 0 – – – 0 0 – – – 0
2–months 13 1 0 0 – – 0 0 0 – – 0
14 2 1 1 – – 1 0 0 – – 1
15 2 1 0 – – 0 0 0 – – 0
16 1 1 0 – – 0 0 0 – – 0
17 1 1 0 – – 0 0 0 – – 0
3–months 18 1 0 0 – 0 0 0 0 – 0
19 1 1 1 – 0 0 0 0 – 1
20 1 0 0 – 0 0 0 0 – 0
21 2 2 2 2 – 1 1 1 1 – 1
22 1 0 0 0 – 0 0 0 0 – 0
23 1 1 1 1 – 1 1 0 0 – 1
24 2 2 2 1 – 1 1 1 1 – 1
6–months 25 x 0 0 0 0 0 0 0 0 0
26 0 0 0 0 0 0 0 0 0 0
27 0 0 0 0 0 0 0 0 0 0
28 1 0 0 0 0 0 0 0 0 0 0
29 1 x 0 0 0 0 0 0 0 0 0
–: the animal was euthanized; x: no CDFI or cTEE measurement; h — hour; m — month
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Figure 2. Example of contrast-enhanced transesopha-
geal echocardiography (cTEE)-score 0 (2-months post-
-left atrial appendage closure); A. Color Doppler flow 
imaging (CDFI): none peri-device flow into left atrial 
appendage (LAA); B. cTEE and time intensity curves 
(TIC): none visible microbubble in LAA, two mixed TICs 
(red, green) in two different locations of LAA were much 
lower than that in left atrium (yellow); C. Gross exami-
nation: fully endothelialization of LAA occluder’s atrial-
surface, and the occluder was well coupled with the 
surrounding tissue.
Figure 3. Example of contrast-enhanced transesopha-
geal echocardiography (cTEE)-score 2 (3-months post- 
-left atrial appendage closure [LAAC]); A. Color Doppler 
flow imaging (CDFI): a width of 2 mm peri-device flow 
into left atrial appendage (LAA); B. cTEE and time inten-
sity curves (TIC): microbubbles got into LAA through 
a communication channel quickly from left atrium (LA) 
to LAA after LAAC, the TIC in LAA (red) was higher than 
the one in LA (yellow) due to the effect of an echo by 
the cover-plate; C. Gross examination: fully neo-intimal 
coverage of occluder’s atrial-surface, the left edge of 
cover-plate was inside LAA, and an irregular fissure 
along the cover-plate’s edge was found and passed with 
a 18-gauge hypodermic needle from LA to LAA.
Figure 4. Histological section of the left atrial appendage closure (LAAC) device’s cover-plate. Sagittal section through 
the center of the left atrial appendage and device in a dog (1-month post-LAAC). Microscopic views showed neo-
intimal coverage over the atrial surface of the cover-plate.
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Table 2. Summary of total score, average score for the contrast-enhanced transesophageal echocar-
diography (cTEE)-score, color Doppler flow imaging (CDFI)-score, histology-score at < 24 h, 1-month, 
2-months, 3-months, and 6-months post-left atrial appendage closure (LAAC).
< 24 hours 1-month 2-months 3-month 6-months
cTEE-score:
Total 24 (17*) 15 (21) 7 (17) 5 (12) 0 (5)
Average 1.41** 0.71 0.41 0.42 0
CDFI-score:
Total 5 (29) 3 (23) 2 (17) 2 (12) 0 (5)
Average 0.17 0.13 0.12 0.17 0
Histology-score:
Total 12 (6) 3 (6) 1 (5) 4 (7) 0 (5)
Average 2 0.5 0.2 0.57 0
*Animal count; **1.41 = 24/7
1 month post-LAO
Neointimal coverage on the atrial surface of the cover-plate
Cross-sections of nitinol wires in the cover-plate
Table 3. Three special cases.
Case Description
No. 11 In case no. 11 (1-month post-LAAC), although the LAAC orifice was blocked by the anchor  
of the device while the cover-disc was in the left atrium (LA) but not attached to the orifice at all; 
the atrial surface of the device, including the central screw, was well covered by the neo-intimal  
tissue, while the incomplete neo-intimal coverage was found on the LAA surface of the cover-
-plate and the short central waist; no communication between LA and LAA was detected.
No. 21 and 24 In case no. 21 (3-months post-LAAC) and case no. 24 (3-months post-LAAC), the gross examination 
showed that in both animals, the left edge of the cover-plate was inside the LAA and there was  
a fissure along the cover-plate’s edge; an 18-gauge hypodermic needle was used to examine 
the hole and could be passed from LA to LAA.
LA — left atrium; LAA — left atrial appendage; LAAC — left atrial appendage closure
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Figure 5. The trends of the average score number of 
contrast-enhanced transesophageal echocardiography 
(cTEE)-score, histology-score, color Doppler flow imag-
ing (CDFI)-score, respectively, from the time before left 
atrial appendage closure (LAAC) (i.e., the time was 0) to 
1-, 30-, 60-, 90-, 180-days post-LAAC.
Table 4 shows the Spearman’s correlations 
of the cTEE, CDFI, and histology scores at time 
points < 24 h, and 30, 60, 90, and 180 days post-
LAAC, respectively. The correlation between cTEE 
and histology scores was superior to that between 
CDFI and histology scores. In Figure 5, shows the 
trend of the average cTEE score tracks with that of 
the histology score at different time points, but the 
curve of the average CDFI score declines sharply 
after device implantation immediately, which is 
distal from that of the histology score.
Discussion
This study introduced a noninvasive visual 
cTEE score method to monitor the communication 
between LA and LAA and predict the progression of 
the LAAC endothelialization process. By compar-
ing with the conventional CDFI method, as well as 
correlating with the post-mortem anatomical and 
histological examinations, we found that cTEE is 
superior to CDFI as a tool for endothelialization 
surveillance.
The post-LAAC healing reactions are similar 
between canine and human, and the canine model is 
suitable for pre-clinical evaluation of LAA occlusion 
devices [2]. Usually, the LAAC devices consist of 
nitinol frame and polyester fabric membrane. If not 
fully endothelialized, the left atrial surface of the 
devices have the potential to promote subsequent 
thrombosis [8]. In a systematic review of DAT after 
LAAC, the overall incidence of DAT was 3.9%. The 
median time from procedure to diagnosis of DAT 
was 1.5 months. These early cases of DAT are re-
lated to delayed device surface endothelialization, 
and the late cases could be secondary to mechani-
cal factors or systemic patient factors [5, 10, 15]. 
Thus, the endothelialization of the LAA occluder’s 
atrial surface is clinically critical in DAT prevention 
postoperatively in patients. Therefore, in the clini-
cal trials, human subjects were given warfarin by 
Watchman devices for 45 days after LAAC. If the 
45-day TEE documented either complete closure 
of the LAA or if peri-device flow was < 5 mm in 
width and there was no visible large thrombus on 
the device, warfarin was discontinued [4, 5]. In-
terestingly, the conformation of LAA surrounding 
structures exhibited variable healing responses 
among different LAAC devices, which might affect 
the progress of endothelialization [2]. In this study, 
LAMaxTM LAAC occluder was applied, and the shape 
of the cover-disc was similar to the disc of ACP.
The following questions remain unanswered: 
Can the device endothelialization process be effec-
tively monitored in vivo? Is the device endotheliali-
zation process associated with the communicated 
flow between LA and LAA? Intriguingly, TEE has 
been applied widely to guide LAAC implantation 
and follow-up anticoagulation. Routine device 
surveillance by TEE at intermediate follow-up pro-
vides the opportunity to assess DAT, peri-device 
leak, device positioning, surrounding structures. 
However, CDFI and cTEE monitor the blood flow 
by different mechanisms [14]. Echo contrast agents 
are lipid-encapsulated microbubbles, which are 
1–7 µm in diameter and similar in size to red blood 
cells. The microbubbles are injected intravenously 
and remain within the blood pool to circulate in 
a manner similar to the red blood cells for a short 
interval. The use of cTEE has been described for 
delineation of an LAA thrombus and distinction 
between spontaneous contrast and thrombus [16]. 
In this study, cTEE was found to be superior to 
CDFI with respect to communication between LA 
0

















Table 4. The correlation coefficients among  
contrast-enhanced transesophageal echocar-
diography (cTEE)-score, color Doppler flow  







cTEE score 1.00 (72) 0.55* (72) 0.95** (29)
CDFI score 0.55* (72) 1.00 (72) 0.16 (29)
Histology score 0.95* (29) 0.16 (29) 1.00 (29)
*Correlation is significant at the 0.01 level (2-tailed).
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and LAA post-LAAC as well as the progression of 
device endothelialization in vivo. The CDFI score 
decreased precipitously immediately post-implan-
tation in > 83% of the cases. This phenomenon 
indicated that in most cases, the communication 
between the LA and LAA reduces to the level be-
low the detection of CDFI after successful device 
deportment. However, the CDFI score of 0 does 
not mean total cessation of the flow as seen in this 
cohort. There were 28/57 cases with a CDFI score 
of 0 zero, but their cTEE scores were 1 or 2, indi-
cating at least partial flow between the LA and the 
LAA. Moreover, the positive predictive value was 
100% with 12 CDFI score-positive (1 or 2) stud-
ies, which also had positive cTEE scores (1 or 2). 
Furthermore, in the set of < 24 h post-LAAC group 
with no neo-intimal coverage on the surface of 
cover-plate, all 6 dogs had a CDFI score of 0 and the 
cTEE score was 1 or 2. This indicated that cTEE 
can detect the communicated flow between LA and 
LAA post-LAAC beyond the resolution of CDFI.
Left atrial appendage closure device surface 
endothelialization is a slow process. It was shown 
that at the end of 1 month, 50% (3/6) of the dogs 
had complete device endothelialization, and by the 
end of 6 months, 100% of the devices’ cover-discs 
were completely covered, and the neoendocar-
dial covering was continuous from the left atrial 
wall to the device. At different time points, the 
histology scores of 15 dogs were 0; also, their 
cTEE and CDFI scores were uniformly 0, with 
a positive predictive value of 100%. However, when 
the endothelial process occurred partially with 
a histology score of 1, the cTEE score was superior 
to the CDFI score. In the 8 dogs with the histology 
score of 1, 7/8 had cTEE score of 1, and one had 
a score of 2, while 2/8 dogs had a CDFI score of 1, 
and the remaining had a score of 0. Overall, the 
cTEE-score was correlated to the histology score 
with a coefficient of 0.95. It is shown that a trend 
of the average cTEE score tracked with that of the 
histology score, but the trend of the average CDFI 
score was far from that of the histology score. This 
finding indicates that cTEE has a better temporal 
resolution than CDFI in monitoring the device 
endothelialization process in vivo.
The present study also showed that the effec-
tive healing response after implantation of LAAC 
devices was related to the achievement of concav-
ity of the cover-plate and less peri-device flow. 
Especially, in 3-months post-LAAC group, both the 
average cTEE and histology scores were higher 
than that of the 2-month post-LAAC group. This 
is due to a higher number of cases with immediate 
post-LAAC peri-device flow present in this group. 
Therefore, it is important to avoid the incidence 
of residual flow during the LAAC procedure; if the 
residual flow is unavoidable, it may be necessary 
to monitor the healing progress by cTEE before 
terminating the use of anticoagulants.
Despite a satisfactory correlation with the 
histology score, the clinical significance of cTEE 
score is yet uncertain. Thus, a large-scale clinical 
study with DAT as the endpoint is imperative. 
For clinical application, it is better to have cTEE 
assessment before 1 month after LAAC. If cTEE 
score remains not 0, cTEE should be done again 
before terminating the OAC. If the residual flow is 
found by CDFI, cTEE could be avoided. Neverthe-
less, we speculated that cTEE could be used as 
a noninvasive tool for endothelialization surveil-
lance after LAAC for the future.
Limitations of the study
The number of animals studied is relatively 
small. Since LAA occlusion devices are usually 
tested in canines before clinical application, the 
present study has extended these methods to 
healthy adult dogs as the animal model. However, 
clinical trials are required for further evaluation.
Conclusions
The noninvasive visual cTEE is feasible and 
reliable to monitor the communication between 
LA and LAA post-LAAC. The cTEE is superior to 
the currently used CDFI to predict the progress 
of neo-intimal coverage on the atrial surface of the 
LAAC device in dogs.
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